MY191043A - Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof - Google Patents
Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereofInfo
- Publication number
- MY191043A MY191043A MYPI2018702294A MYPI2018702294A MY191043A MY 191043 A MY191043 A MY 191043A MY PI2018702294 A MYPI2018702294 A MY PI2018702294A MY PI2018702294 A MYPI2018702294 A MY PI2018702294A MY 191043 A MY191043 A MY 191043A
- Authority
- MY
- Malaysia
- Prior art keywords
- pemetrexed
- pharmaceutical composition
- stability
- present
- pharmaceutically acceptable
- Prior art date
Links
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title abstract 5
- 229960005079 pemetrexed Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 abstract 3
- 238000011109 contamination Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150178339A KR101693675B1 (ko) | 2015-12-14 | 2015-12-14 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
| PCT/KR2016/014594 WO2017105059A1 (ko) | 2015-12-14 | 2016-12-13 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY191043A true MY191043A (en) | 2022-05-30 |
Family
ID=57832487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018702294A MY191043A (en) | 2015-12-14 | 2016-12-13 | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10792285B2 (enExample) |
| EP (1) | EP3391908A4 (enExample) |
| JP (3) | JP2019502751A (enExample) |
| KR (1) | KR101693675B1 (enExample) |
| CN (1) | CN108463251A (enExample) |
| HK (1) | HK1255313A1 (enExample) |
| MY (1) | MY191043A (enExample) |
| PH (1) | PH12018501274A1 (enExample) |
| WO (1) | WO2017105059A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019244965A1 (ja) * | 2018-06-20 | 2019-12-26 | 日本化薬株式会社 | ペメトレキセドナトリウム注射用溶液製剤、並びにその製造方法 |
| CN116474218A (zh) * | 2019-06-28 | 2023-07-25 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
| JP2025511651A (ja) * | 2022-06-09 | 2025-04-16 | 上海雲晟研新生物科技有限公司 | ペメトレキセド二ナトリウム液体組成物、その製造方法及び応用 |
| JP2024006619A (ja) | 2022-07-04 | 2024-01-17 | セイコーエプソン株式会社 | 印刷装置、情報処理装置、情報処理システム、処理方法、及び、プログラム |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| US6686365B2 (en) | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| MXPA02007191A (es) * | 2000-02-04 | 2002-12-09 | Lilly Co Eli | Composicion farmaceutica que comprende permetrexed junto con monotioglicerol, l-cisteina o acido tioglicolico. |
| JP2013540104A (ja) * | 2010-07-28 | 2013-10-31 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 |
| KR20130122065A (ko) | 2012-04-30 | 2013-11-07 | 씨제이제일제당 (주) | 페메트렉시드를 함유하는 안정화된 주사용 액상 제제 |
| EP2666463A1 (en) * | 2012-05-21 | 2013-11-27 | Synthon BV | Stabilized liquid composition comprising pemetrexed |
| PT2854768T (pt) * | 2012-05-30 | 2017-05-19 | Fresenius Kabi Oncology Ltd | Composições farmacêuticas de pemetrexed |
| DE102012010774A1 (de) * | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
| KR101260636B1 (ko) | 2012-11-29 | 2013-05-13 | 씨제이제일제당 (주) | 안정화된 페메트렉시드 제제 |
| KR101485243B1 (ko) * | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
| JP6094388B2 (ja) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
| EP3040074B1 (en) * | 2013-10-03 | 2018-07-25 | Fujifilm Corporation | Injection preparation and method for producing same |
| JP6099557B2 (ja) * | 2013-12-27 | 2017-03-22 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| KR101574875B1 (ko) * | 2014-02-13 | 2015-12-04 | 건양대학교산학협력단 | 안정화된 페니실린 복합 현탁 제제 |
| PL3124026T3 (pl) * | 2014-03-28 | 2019-03-29 | Fujifilm Corporation | Preparat iniekcyjny i sposób jego wytwarzania |
| US20170340639A1 (en) * | 2015-03-26 | 2017-11-30 | Ftf Pharma Private Limited | Pharmaceutical composition of pemetrexed |
| KR101919436B1 (ko) * | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
-
2015
- 2015-12-14 KR KR1020150178339A patent/KR101693675B1/ko active Active
-
2016
- 2016-12-13 US US16/061,450 patent/US10792285B2/en not_active Expired - Fee Related
- 2016-12-13 JP JP2018550317A patent/JP2019502751A/ja active Pending
- 2016-12-13 CN CN201680073091.9A patent/CN108463251A/zh active Pending
- 2016-12-13 WO PCT/KR2016/014594 patent/WO2017105059A1/ko not_active Ceased
- 2016-12-13 MY MYPI2018702294A patent/MY191043A/en unknown
- 2016-12-13 HK HK18114448.9A patent/HK1255313A1/zh unknown
- 2016-12-13 EP EP16876001.5A patent/EP3391908A4/en not_active Withdrawn
-
2018
- 2018-06-14 PH PH12018501274A patent/PH12018501274A1/en unknown
-
2020
- 2020-05-27 JP JP2020091920A patent/JP2020125359A/ja active Pending
-
2022
- 2022-05-31 JP JP2022088229A patent/JP2022107687A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255313A1 (zh) | 2019-08-16 |
| US20200261458A1 (en) | 2020-08-20 |
| PH12018501274A1 (en) | 2019-02-04 |
| US10792285B2 (en) | 2020-10-06 |
| EP3391908A1 (en) | 2018-10-24 |
| EP3391908A4 (en) | 2019-08-07 |
| CN108463251A (zh) | 2018-08-28 |
| JP2020125359A (ja) | 2020-08-20 |
| JP2019502751A (ja) | 2019-01-31 |
| JP2022107687A (ja) | 2022-07-22 |
| WO2017105059A1 (ko) | 2017-06-22 |
| KR101693675B1 (ko) | 2017-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| IN2015KN00005A (enExample) | ||
| PH12018501274A1 (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| PE20140616A1 (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) | |
| EA033444B1 (ru) | Снижение вязкости фармацевтических составов | |
| MY189913A (en) | Preparation containing tetracyclic compound at high dose | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| NZ702342A (en) | Pharmaceutical formulation | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX369571B (es) | Composicion para prevenir o tratar enfermedades del higado graso. | |
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| PH12017501828B1 (en) | Stabilized pharmaceutical composition and method for preparing same | |
| RU2013146452A (ru) | Инъекционный или инфузионный раствор триазавирина для лечения вирусных инфекций | |
| SG194458A1 (en) | Solid pharmaceutical composition | |
| MY203965A (en) | Injectable formulations of paracetamol | |
| NZ705340A (en) | Amine salt and crystals thereof | |
| MY180369A (en) | Pharmaceutical composition for external use | |
| MY192061A (en) | Pharmaceutical composition for external use | |
| HK1226310A1 (en) | Liquid protein formulations containing water soluble organic dyes | |
| EA201800360A1 (ru) | Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина | |
| IN2014MU01178A (enExample) | ||
| IN2013MU03613A (enExample) | ||
| IN2014MU01179A (enExample) | ||
| EA027609B8 (ru) | Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа | |
| UA109242U (uk) | Стабільна фармацевтична композиція, що містить інгібітор протеасом |